ID   SIAH1_HUMAN             Reviewed;         282 AA.
AC   Q8IUQ4; A0FKF3; O43269; Q49A58; Q92880;
DT   26-APR-2004, integrated into UniProtKB/Swiss-Prot.
DT   26-APR-2004, sequence version 2.
DT   12-APR-2017, entry version 155.
DE   RecName: Full=E3 ubiquitin-protein ligase SIAH1;
DE            EC=2.3.2.27;
DE   AltName: Full=RING-type E3 ubiquitin transferase SIAH1 {ECO:0000305};
DE   AltName: Full=Seven in absentia homolog 1;
DE            Short=Siah-1;
DE   AltName: Full=Siah-1a;
GN   Name=SIAH1; Synonyms=HUMSIAH;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Intestinal epithelium;
RX   PubMed=8799150; DOI=10.1073/pnas.93.17.9039;
RA   Nemani M., Linares-Cruz G., Bruzzoni-Giovanelli H., Roperch J.-P.,
RA   Tuynder M., Bougueleret L., Cherif D., Medhioub M., Pasturaud P.,
RA   Alvaro V., Der Sarkissan H., Cazes L., Le Paslier D., Le Gall I.,
RA   Israeli D., Dausset J., Sigaux F., Chumakov I., Oren M., Calvo F.,
RA   Amson R.B., Cohen D., Telerman A.;
RT   "Activation of the human homologue of the Drosophila sina gene in
RT   apoptosis and tumor suppression.";
RL   Proc. Natl. Acad. Sci. U.S.A. 93:9039-9042(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), SUBCELLULAR LOCATION, AND
RP   TISSUE SPECIFICITY.
RC   TISSUE=Fetal brain;
RX   PubMed=9403064; DOI=10.1006/geno.1997.4997;
RA   Hu G., Chung Y.-L., Glover T., Valentine V., Look A.T., Fearon E.R.;
RT   "Characterization of human homologs of the Drosophila seven in
RT   absentia (sina) gene.";
RL   Genomics 46:103-111(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=10956387;
RX   DOI=10.1002/1097-0215(20000915)87:6<794::AID-IJC5>3.0.CO;2-B;
RA   Medhioub M., Vaury C., Hamelin R., Thomas G.;
RT   "Lack of somatic mutation in the coding sequence of SIAH1 in tumors
RT   hemizygous for this candidate tumor suppressor gene.";
RL   Int. J. Cancer 87:794-797(2000).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3).
RX   PubMed=17420721; DOI=10.1038/sj.onc.1210449;
RA   Mei Y., Xie C., Xie W., Wu Z., Wu M.;
RT   "Siah-1S, a novel splice variant of Siah-1 (seven in absentia
RT   homolog), counteracts Siah-1-mediated downregulation of beta-
RT   catenin.";
RL   Oncogene 26:6319-6331(2007).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Retina;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Brain, Pancreas, and Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   FUNCTION IN DEGRADATION OF DCC, SUBCELLULAR LOCATION, AND INTERACTION
RP   WITH UBE2I.
RX   PubMed=9334332; DOI=10.1101/gad.11.20.2701;
RA   Hu G., Zhang S., Vidal M., Baer J.L., Xu T., Fearon E.R.;
RT   "Mammalian homologs of seven in absentia regulate DCC via the
RT   ubiquitin-proteasome pathway.";
RL   Genes Dev. 11:2701-2714(1997).
RN   [8]
RP   INTERACTION WITH BAG1, AND SUBCELLULAR LOCATION.
RX   PubMed=9582267; DOI=10.1093/emboj/17.10.2736;
RA   Matsuzawa S., Takayama S., Froesch B.A., Zapata J.M., Reed J.C.;
RT   "p53-inducible human homologue of Drosophila seven in absentia (Siah)
RT   inhibits cell growth: suppression by BAG-1.";
RL   EMBO J. 17:2736-2747(1998).
RN   [9]
RP   FUNCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF GLU-40; CYS-41;
RP   CYS-44; CYS-55; HIS-59; ARG-66; LYS-68; ARG-76; HIS-152; HIS-202 AND
RP   LEU-211.
RX   PubMed=9858595; DOI=10.1128/MCB.19.1.724;
RA   Hu G., Fearon E.R.;
RT   "Siah-1 N-terminal RING domain is required for proteolysis function,
RT   and C-terminal sequences regulate oligomerization and binding to
RT   target proteins.";
RL   Mol. Cell. Biol. 19:724-732(1999).
RN   [10]
RP   FUNCTION IN DEGRADATION OF KIF22, AND INTERACTION WITH ALPHA-TUBULIN.
RX   PubMed=11146551; DOI=10.1038/sj.onc.1204002;
RA   Germani A., Bruzzoni-Giovanelli H., Fellous A., Gisselbrecht S.,
RA   Varin-Blank N., Calvo F.;
RT   "SIAH-1 interacts with alpha-tubulin and degrades the kinesin Kid by
RT   the proteasome pathway during mitosis.";
RL   Oncogene 19:5997-6006(2000).
RN   [11]
RP   FUNCTION IN DEGRADATION OF MYB.
RX   PubMed=10747903; DOI=10.1074/jbc.M000372200;
RA   Tanikawa J., Ichikawa-Iwata E., Kanei-Ishii C., Nakai A.,
RA   Matsuzawa S., Reed J.C., Ishii S.;
RT   "p53 suppresses the c-Myb-induced activation of heat shock
RT   transcription factor 3.";
RL   J. Biol. Chem. 275:15578-15585(2000).
RN   [12]
RP   FUNCTION IN DEGRADATION OF CTNNB1, AND SUBUNIT OF A COMPLEX WITH
RP   UBE2D1; CACYBP; SKP1; APC AND TBL1X.
RX   PubMed=11389839; DOI=10.1016/S1097-2765(01)00242-8;
RA   Matsuzawa S., Reed J.C.;
RT   "Siah-1, SIP, and Ebi collaborate in a novel pathway for beta-catenin
RT   degradation linked to p53 responses.";
RL   Mol. Cell 7:915-926(2001).
RN   [13]
RP   FUNCTION IN DEGRADATION OF CTNNB1.
RX   PubMed=11389840; DOI=10.1016/S1097-2765(01)00241-6;
RA   Liu J., Stevens J., Rote C.A., Yost H.J., Hu Y., Neufeld K.L.,
RA   White R.L., Matsunami N.;
RT   "Siah-1 mediates a novel beta-catenin degradation pathway linking p53
RT   to the adenomatous polyposis coli protein.";
RL   Mol. Cell 7:927-936(2001).
RN   [14]
RP   FUNCTION IN DEGRADATION OF POU2AF1, AND SUBCELLULAR LOCATION.
RX   PubMed=11483517; DOI=10.1093/emboj/20.15.4143;
RA   Tiedt R., Bartholdy B.A., Matthias G., Newell J.W., Matthias P.;
RT   "The RING finger protein Siah-1 regulates the level of the
RT   transcriptional coactivator OBF-1.";
RL   EMBO J. 20:4143-4152(2001).
RN   [15]
RP   FUNCTION IN DEGRADATION OF POU2AF1.
RX   PubMed=11483518; DOI=10.1093/emboj/20.15.4153;
RA   Boehm J., He Y., Greiner A., Staudt L., Wirth T.;
RT   "Regulation of BOB.1/OBF.1 stability by SIAH.";
RL   EMBO J. 20:4153-4162(2001).
RN   [16]
RP   FUNCTION IN DEGRADATION OF NUMB.
RX   PubMed=11752454; DOI=10.1073/pnas.261571998;
RA   Susini L., Passer B.J., Amzallag-Elbaz N., Juven-Gershon T.,
RA   Prieur S., Privat N., Tuynder M., Gendron M.-C., Israeel A., Amson R.,
RA   Oren M., Telerman A.;
RT   "Siah-1 binds and regulates the function of Numb.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:15067-15072(2001).
RN   [17]
RP   FUNCTION IN DEGRADATION OF KLF10.
RX   PubMed=12072443; DOI=10.1074/jbc.M204812200;
RA   Johnsen S.A., Subramaniam M., Monroe D.G., Janknecht R.,
RA   Spelsberg T.C.;
RT   "Modulation of transforming growth factor beta (TGFbeta)/Smad
RT   transcriptional responses through targeted degradation of TGFbeta-
RT   inducible early gene-1 by human seven in absentia homologue.";
RL   J. Biol. Chem. 277:30754-30759(2002).
RN   [18]
RP   FUNCTION IN DEGRADATION OF SNCAIP, AND SUBCELLULAR LOCATION.
RX   PubMed=14506261; DOI=10.1074/jbc.M306347200;
RA   Nagano Y., Yamashita H., Takahashi T., Kishida S., Nakamura T.,
RA   Iseki E., Hattori N., Mizuno Y., Kikuchi A., Matsumoto M.;
RT   "Siah-1 facilitates ubiquitination and degradation of synphilin-1.";
RL   J. Biol. Chem. 278:51504-51514(2003).
RN   [19]
RP   INTERACTION WITH PEG10.
RX   PubMed=12810624;
RA   Okabe H., Satoh S., Furukawa Y., Kato T., Hasegawa S., Nakajima Y.,
RA   Yamaoka Y., Nakamura Y.;
RT   "Involvement of PEG10 in human hepatocellular carcinogenesis through
RT   interaction with SIAH1.";
RL   Cancer Res. 63:3043-3048(2003).
RN   [20]
RP   TISSUE SPECIFICITY.
RX   PubMed=12557228; DOI=10.1002/gcc.10170;
RA   Matsuo K., Satoh S., Okabe H., Nomura A., Maeda T., Yamaoka Y.,
RA   Ikai I.;
RT   "SIAH1 inactivation correlates with tumor progression in
RT   hepatocellular carcinomas.";
RL   Genes Chromosomes Cancer 36:283-291(2003).
RN   [21]
RP   FUNCTION IN DEGRADATION OF RBBP8.
RX   PubMed=14654780; DOI=10.1038/sj.onc.1206994;
RA   Germani A., Prabel A., Mourah S., Podgorniak M.-P., Di Carlo A.,
RA   Ehrlich R., Gisselbrecht S., Varin-Blank N., Calvo F.,
RA   Bruzzoni-Giovanelli H.;
RT   "SIAH-1 interacts with CtIP and promotes its degradation by the
RT   proteasome pathway.";
RL   Oncogene 22:8845-8851(2003).
RN   [22]
RP   INTERACTION WITH CACYBP, AND MUTANTS A; B; C; D AND E.
RX   PubMed=12421809; DOI=10.1074/jbc.M210263200;
RA   Matsuzawa S., Li C., Ni C.-Z., Takayama S., Reed J.C., Ely K.R.;
RT   "Structural analysis of Siah1 and its interactions with Siah-
RT   interacting protein (SIP).";
RL   J. Biol. Chem. 278:1837-1840(2003).
RN   [23]
RP   INTERACTION WITH KHDRBS3.
RX   PubMed=15163637; DOI=10.1093/hmg/ddh165;
RA   Venables J.P., Dalgliesh C., Paronetto M.P., Skitt L., Thornton J.K.,
RA   Saunders P.T., Sette C., Jones K.T., Elliott D.J.;
RT   "SIAH1 targets the alternative splicing factor T-STAR for degradation
RT   by the proteasome.";
RL   Hum. Mol. Genet. 13:1525-1534(2004).
RN   [24]
RP   FUNCTION IN DEGRADATION OF PML, AND MUTANTS A AND D.
RX   PubMed=14645235; DOI=10.1074/jbc.M306407200;
RA   Fanelli M., Fantozzi A., De Luca P., Caprodossi S., Matsuzawa S.,
RA   Lazar M.A., Pelicci P.G., Minucci S.;
RT   "The coiled-coil domain is the structural determinant for mammalian
RT   homologues of Drosophila Sina-mediated degradation of promyelocytic
RT   leukemia protein and other tripartite motif proteins by the
RT   proteasome.";
RL   J. Biol. Chem. 279:5374-5379(2004).
RN   [25]
RP   FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH SNCAIP AND SNCA, AND
RP   MUTAGENESIS OF CYS-55; HIS-59 AND CYS-72.
RX   PubMed=15064394; DOI=10.1073/pnas.0401081101;
RA   Liani E., Eyal A., Avraham E., Shemer R., Szargel R., Berg D.,
RA   Bornemann A., Riess O., Ross C.A., Rott R., Engelender S.;
RT   "Ubiquitylation of synphilin-1 and alpha-synuclein by SIAH and its
RT   presence in cellular inclusions and Lewy bodies imply a role in
RT   Parkinson's disease.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:5500-5505(2004).
RN   [26]
RP   FUNCTION, MUTAGENESIS OF SER-19 AND CYS-44, INTERACTION WITH HIPK2,
RP   AND PHOSPHORYLATION AT SER-19 BY ATM AND ATR.
RX   PubMed=18536714; DOI=10.1038/ncb1743;
RA   Winter M., Sombroek D., Dauth I., Moehlenbrink J., Scheuermann K.,
RA   Crone J., Hofmann T.G.;
RT   "Control of HIPK2 stability by ubiquitin ligase Siah-1 and checkpoint
RT   kinases ATM and ATR.";
RL   Nat. Cell Biol. 10:812-824(2008).
RN   [27]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [28]
RP   INTERACTION WITH SNCAIP, ENZYME REGULATION, AND FUNCTION.
RX   PubMed=19224863; DOI=10.1074/jbc.M805990200;
RA   Szargel R., Rott R., Eyal A., Haskin J., Shani V., Balan L.,
RA   Wolosker H., Engelender S.;
RT   "Synphilin-1A inhibits seven in absentia homolog (SIAH) and modulates
RT   alpha-synuclein monoubiquitylation and inclusion formation.";
RL   J. Biol. Chem. 284:11706-11716(2009).
RN   [29]
RP   FUNCTION IN UBIQUITINATION OF FLT3.
RX   PubMed=20508617; DOI=10.1038/leu.2010.114;
RA   Buchwald M., Pietschmann K., Muller J.P., Bohmer F.D., Heinzel T.,
RA   Kramer O.H.;
RT   "Ubiquitin conjugase UBCH8 targets active FMS-like tyrosine kinase 3
RT   for proteasomal degradation.";
RL   Leukemia 24:1412-1421(2010).
RN   [30]
RP   FUNCTION.
RX   PubMed=22483617; DOI=10.1016/j.molcel.2012.03.007;
RA   Liu M., Hsu J., Chan C., Li Z., Zhou Q.;
RT   "The ubiquitin ligase Siah1 controls ELL2 stability and formation of
RT   super elongation complexes to modulate gene transcription.";
RL   Mol. Cell 46:325-334(2012).
RN   [31]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 90-282 IN COMPLEX WITH ZINC
RP   IONS AND CACYBP, FUNCTION, MUTAGENESIS OF 198-LYS--ASP-200 AND
RP   MET-252, AND INTERACTION WITH CACYBP.
RX   PubMed=16085652; DOI=10.1074/jbc.M506707200;
RA   Santelli E., Leone M., Li C., Fukushima T., Preece N.E., Olson A.J.,
RA   Ely K.R., Reed J.C., Pellecchia M., Liddington R.C., Matsuzawa S.;
RT   "Structural analysis of Siah1-Siah-interacting protein interactions
RT   and insights into the assembly of an E3 ligase multiprotein complex.";
RL   J. Biol. Chem. 280:34278-34287(2005).
CC   -!- FUNCTION: E3 ubiquitin-protein ligase that mediates ubiquitination
CC       and subsequent proteasomal degradation of target proteins. E3
CC       ubiquitin ligases accept ubiquitin from an E2 ubiquitin-
CC       conjugating enzyme in the form of a thioester and then directly
CC       transfers the ubiquitin to targeted substrates. Mediates E3
CC       ubiquitin ligase activity either through direct binding to
CC       substrates or by functioning as the essential RING domain subunit
CC       of larger E3 complexes. Triggers the ubiquitin-mediated
CC       degradation of many substrates, including proteins involved in
CC       transcription regulation (ELL2, MYB, POU2AF1, PML and RBBP8), a
CC       cell surface receptor (DCC), the cell-surface receptor-type
CC       tyrosine kinase FLT3, the cytoplasmic signal transduction
CC       molecules (KLF10/TIEG1 and NUMB), an antiapoptotic protein (BAG1),
CC       a microtubule motor protein (KIF22), a protein involved in
CC       synaptic vesicle function in neurons (SYP), a structural protein
CC       (CTNNB1) and SNCAIP. Confers constitutive instability to HIPK2
CC       through proteasomal degradation. It is thereby involved in many
CC       cellular processes such as apoptosis, tumor suppression, cell
CC       cycle, axon guidance, transcription regulation, spermatogenesis
CC       and TNF-alpha signaling. Has some overlapping function with SIAH2.
CC       Induces apoptosis in cooperation with PEG3. Upon nitric oxid (NO)
CC       generation that follows apoptotic stimulation, interacts with S-
CC       nitrosylated GAPDH, mediating the translocation of GAPDH to the
CC       nucleus. GAPDH acts as a stabilizer of SIAH1, facilitating the
CC       degradation of nuclear proteins. {ECO:0000269|PubMed:10747903,
CC       ECO:0000269|PubMed:11146551, ECO:0000269|PubMed:11389839,
CC       ECO:0000269|PubMed:11389840, ECO:0000269|PubMed:11483517,
CC       ECO:0000269|PubMed:11483518, ECO:0000269|PubMed:11752454,
CC       ECO:0000269|PubMed:12072443, ECO:0000269|PubMed:14506261,
CC       ECO:0000269|PubMed:14645235, ECO:0000269|PubMed:14654780,
CC       ECO:0000269|PubMed:15064394, ECO:0000269|PubMed:16085652,
CC       ECO:0000269|PubMed:18536714, ECO:0000269|PubMed:19224863,
CC       ECO:0000269|PubMed:20508617, ECO:0000269|PubMed:22483617,
CC       ECO:0000269|PubMed:9334332, ECO:0000269|PubMed:9858595}.
CC   -!- CATALYTIC ACTIVITY: S-ubiquitinyl-[E2 ubiquitin-conjugating
CC       enzyme]-L-cysteine + [acceptor protein]-L-lysine = [E2 ubiquitin-
CC       conjugating enzyme]-L-cysteine + N(6)-ubiquitinyl-[acceptor
CC       protein]-L-lysine.
CC   -!- ENZYME REGULATION: Inhibited by interaction with SNCAIP (isoform
CC       2, but not isoform 1). May be inhibited by interaction with PEG10.
CC       {ECO:0000269|PubMed:19224863}.
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC   -!- SUBUNIT: Homodimer. Interacts with group 1 glutamate receptors
CC       GRM1 and GRM5. Interacts with DAB1, which may inhibit its
CC       activity. Interacts with UBE2E2. Interacts with PEG3. Interacts
CC       with GAPDH; leading to stabilize SIAH1 (By similarity). Component
CC       of some large E3 complex composed of UBE2D1, SIAH1, CACYBP/SIP,
CC       SKP1, APC and TBL1X. Interacts with UBE2I. Interacts with alpha-
CC       tubulin. Interacts with PEG10, which may inhibit its activity.
CC       Interacts with KHDRBS3. Interacts with SNCAIP and HIPK2.
CC       {ECO:0000250, ECO:0000269|PubMed:11146551,
CC       ECO:0000269|PubMed:11389839, ECO:0000269|PubMed:12421809,
CC       ECO:0000269|PubMed:12810624, ECO:0000269|PubMed:15064394,
CC       ECO:0000269|PubMed:15163637, ECO:0000269|PubMed:16085652,
CC       ECO:0000269|PubMed:18536714, ECO:0000269|PubMed:19224863,
CC       ECO:0000269|PubMed:9334332, ECO:0000269|PubMed:9582267}.
CC   -!- INTERACTION:
CC       Self; NbExp=3; IntAct=EBI-747107, EBI-747107;
CC       Q59GP6:-; NbExp=3; IntAct=EBI-747107, EBI-10243413;
CC       Q9NRN7:AASDHPPT; NbExp=3; IntAct=EBI-747107, EBI-740884;
CC       Q9UHB7:AFF4; NbExp=5; IntAct=EBI-747107, EBI-395282;
CC       Q9UHB7-2:AFF4; NbExp=5; IntAct=EBI-747107, EBI-10261324;
CC       P29972:AQP1; NbExp=3; IntAct=EBI-747107, EBI-745213;
CC       Q7Z3E5-2:ARMC9; NbExp=3; IntAct=EBI-747107, EBI-10256990;
CC       O15265:ATXN7; NbExp=2; IntAct=EBI-747107, EBI-708350;
CC       P41182:BCL6; NbExp=3; IntAct=EBI-747107, EBI-765407;
CC       Q17R99:C14orf105; NbExp=3; IntAct=EBI-747107, EBI-10238351;
CC       P40121:CAPG; NbExp=3; IntAct=EBI-747107, EBI-4291044;
CC       Q9UJX2:CDC23; NbExp=3; IntAct=EBI-747107, EBI-396137;
CC       P49427:CDC34; NbExp=3; IntAct=EBI-747107, EBI-975634;
CC       Q8N619:CDK5R1; NbExp=3; IntAct=EBI-747107, EBI-10266998;
CC       Q8TAM4:CDK5R1; NbExp=3; IntAct=EBI-747107, EBI-10271838;
CC       Q9UJV9:DDX41; NbExp=3; IntAct=EBI-747107, EBI-1046350;
CC       Q9Y5T4:DNAJC15; NbExp=3; IntAct=EBI-747107, EBI-10329228;
CC       O14645:DNALI1; NbExp=3; IntAct=EBI-747107, EBI-395638;
CC       P29692:EEF1D; NbExp=4; IntAct=EBI-747107, EBI-358607;
CC       Q8N2X6:EXOC3-AS1; NbExp=3; IntAct=EBI-747107, EBI-749333;
CC       Q86YD7:FAM90A1; NbExp=3; IntAct=EBI-747107, EBI-6658203;
CC       Q01543:FLI1; NbExp=3; IntAct=EBI-747107, EBI-2271018;
CC       Q8TAN2:FZD9; NbExp=3; IntAct=EBI-747107, EBI-741016;
CC       Q8WTR4:GDPD5; NbExp=3; IntAct=EBI-747107, EBI-2833203;
CC       P62805:HIST2H4B; NbExp=3; IntAct=EBI-747107, EBI-302023;
CC       P05111:INHA; NbExp=3; IntAct=EBI-11522811, EBI-10194422;
CC       Q9BW62:KATNAL1; NbExp=3; IntAct=EBI-747107, EBI-743591;
CC       P78508:KCNJ10; NbExp=3; IntAct=EBI-747107, EBI-9117877;
CC       Q8IZA0:KIAA0319L; NbExp=3; IntAct=EBI-747107, EBI-5240269;
CC       Q5T5P2-6:KIAA1217; NbExp=3; IntAct=EBI-747107, EBI-10188326;
CC       Q9H0B3:KIAA1683; NbExp=3; IntAct=EBI-747107, EBI-745878;
CC       O60333:KIF1B; NbExp=3; IntAct=EBI-747107, EBI-465633;
CC       Q9BVG8:KIFC3; NbExp=3; IntAct=EBI-747107, EBI-2125614;
CC       Q53H82:LACTB2; NbExp=3; IntAct=EBI-747107, EBI-3943430;
CC       Q13394:MAB21L1; NbExp=3; IntAct=EBI-747107, EBI-10229059;
CC       P53778:MAPK12; NbExp=3; IntAct=EBI-747107, EBI-602406;
CC       O60336:MAPKBP1; NbExp=3; IntAct=EBI-747107, EBI-947402;
CC       Q70IA8:MOB3C; NbExp=3; IntAct=EBI-747107, EBI-9679267;
CC       Q9H2K0:MTIF3; NbExp=3; IntAct=EBI-747107, EBI-3923617;
CC       P20591:MX1; NbExp=3; IntAct=EBI-747107, EBI-929476;
CC       Q99836:MYD88; NbExp=3; IntAct=EBI-747107, EBI-447677;
CC       Q92692:NECTIN2; NbExp=3; IntAct=EBI-747107, EBI-718419;
CC       Q9H3P2:NELFA; NbExp=3; IntAct=EBI-747107, EBI-5461341;
CC       Q9H6R4-4:NOL6; NbExp=3; IntAct=EBI-747107, EBI-10307896;
CC       P35372:OPRM1; NbExp=4; IntAct=EBI-747107, EBI-2624570;
CC       Q96DC9:OTUB2; NbExp=3; IntAct=EBI-747107, EBI-746259;
CC       Q86TG7:PEG10; NbExp=3; IntAct=EBI-747107, EBI-2858265;
CC       P08237:PFKM; NbExp=3; IntAct=EBI-747107, EBI-514788;
CC       Q8IXK0:PHC2; NbExp=5; IntAct=EBI-747107, EBI-713786;
CC       Q16633:POU2AF1; NbExp=2; IntAct=EBI-747107, EBI-943588;
CC       Q64693:Pou2af1 (xeno); NbExp=5; IntAct=EBI-747107, EBI-943530;
CC       F1T0A5:PRPF31; NbExp=3; IntAct=EBI-747107, EBI-10177194;
CC       Q8WWY3:PRPF31; NbExp=3; IntAct=EBI-11522811, EBI-1567797;
CC       P86479:PRR20C; NbExp=5; IntAct=EBI-747107, EBI-10172814;
CC       Q8WUK0:PTPMT1; NbExp=3; IntAct=EBI-747107, EBI-7199479;
CC       Q9UHX1:PUF60; NbExp=7; IntAct=EBI-747107, EBI-1053259;
CC       P11216:PYGB; NbExp=3; IntAct=EBI-747107, EBI-1047231;
CC       Q2TAL8:QRICH1; NbExp=3; IntAct=EBI-747107, EBI-2798044;
CC       Q14088:RAB33A; NbExp=3; IntAct=EBI-747107, EBI-744685;
CC       Q96B01:RAD51AP1; NbExp=3; IntAct=EBI-747107, EBI-1178724;
CC       Q96B01-2:RAD51AP1; NbExp=3; IntAct=EBI-747107, EBI-1178743;
CC       Q9Y4B4:RAD54L2; NbExp=3; IntAct=EBI-747107, EBI-948156;
CC       Q86WX3:RPS19BP1; NbExp=3; IntAct=EBI-747107, EBI-4479407;
CC       O00560:SDCBP; NbExp=3; IntAct=EBI-747107, EBI-727004;
CC       O43236-6:SEPT4; NbExp=2; IntAct=EBI-747107, EBI-4372019;
CC       Q69ZI1:Sh3rf1 (xeno); NbExp=5; IntAct=EBI-747107, EBI-957380;
CC       Q8NEY3:SPATA4; NbExp=3; IntAct=EBI-747107, EBI-7067221;
CC       Q9H0A9:SPATC1L; NbExp=3; IntAct=EBI-747107, EBI-372911;
CC       O43581:SYT7; NbExp=3; IntAct=EBI-747107, EBI-10184345;
CC       Q9NU19:TBC1D22B; NbExp=3; IntAct=EBI-747107, EBI-8787464;
CC       Q9BTV4:TMEM43; NbExp=3; IntAct=EBI-747107, EBI-721293;
CC       Q6FIE9:TOLLIP; NbExp=3; IntAct=EBI-747107, EBI-10249783;
CC       Q13625-3:TP53BP2; NbExp=3; IntAct=EBI-747107, EBI-10175039;
CC       P36406:TRIM23; NbExp=3; IntAct=EBI-747107, EBI-740098;
CC       P14373:TRIM27; NbExp=3; IntAct=EBI-747107, EBI-719493;
CC       Q9C029:TRIM7; NbExp=3; IntAct=EBI-747107, EBI-2813981;
CC       P61086:UBE2K; NbExp=4; IntAct=EBI-747107, EBI-473850;
CC       O95045:UPP2; NbExp=3; IntAct=EBI-747107, EBI-10191025;
CC       Q9UBK9:UXT; NbExp=3; IntAct=EBI-747107, EBI-357355;
CC       Q96HA8:WDYHV1; NbExp=3; IntAct=EBI-747107, EBI-741158;
CC       P69713:X (xeno); NbExp=4; IntAct=EBI-747107, EBI-7088789;
CC       P98170:XIAP; NbExp=3; IntAct=EBI-747107, EBI-517127;
CC       A2RRL9:ZBP1; NbExp=3; IntAct=EBI-747107, EBI-10173066;
CC       Q8TBK6:ZCCHC10; NbExp=3; IntAct=EBI-747107, EBI-597063;
CC       Q8WW36:ZCCHC13; NbExp=3; IntAct=EBI-747107, EBI-954111;
CC       Q9BQ24:ZFYVE21; NbExp=3; IntAct=EBI-747107, EBI-2849569;
CC       Q9HA38:ZMAT3; NbExp=3; IntAct=EBI-747107, EBI-2548480;
CC       Q9UQR1:ZNF148; NbExp=3; IntAct=EBI-747107, EBI-2688184;
CC       Q96KM6:ZNF512B; NbExp=3; IntAct=EBI-747107, EBI-1049952;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Note=Predominantly
CC       cytoplasmic. Partially nuclear.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q8IUQ4-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q8IUQ4-2; Sequence=VSP_010166;
CC       Name=3; Synonyms=Siah-1S;
CC         IsoId=Q8IUQ4-3; Sequence=VSP_029210, VSP_029211;
CC   -!- TISSUE SPECIFICITY: Widely expressed at a low level. Down-
CC       regulated in advanced hepatocellular carcinomas.
CC       {ECO:0000269|PubMed:12557228, ECO:0000269|PubMed:9403064}.
CC   -!- INDUCTION: May be induced by p53/TP53, suggesting that it may be
CC       required to modulate p53/TP53 response. The relevance of such
CC       activity in vivo is however unclear and may not exist.
CC   -!- DOMAIN: The RING-type zinc finger domain is essential for
CC       ubiquitin ligase activity.
CC   -!- DOMAIN: The SBD domain (substrate-binding domain) mediates the
CC       homodimerization and the interaction with substrate proteins. It
CC       is related to the TRAF family. {ECO:0000250}.
CC   -!- PTM: Phosphorylated on Ser-19 by ATM and ATR. This phosphorylation
CC       disrupts SIAH1 interaction with HIPK2, and subsequent proteasomal
CC       degradation of HIPK2. {ECO:0000269|PubMed:18536714}.
CC   -!- SIMILARITY: Belongs to the SINA (Seven in absentia) family.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U63295; AAC12950.1; -; mRNA.
DR   EMBL; U76247; AAC51907.1; -; mRNA.
DR   EMBL; AJ400626; CAC35542.1; -; Genomic_DNA.
DR   EMBL; EF026094; ABK15529.1; -; mRNA.
DR   EMBL; BX647064; CAE46191.1; -; mRNA.
DR   EMBL; BC035562; AAH35562.1; -; mRNA.
DR   EMBL; BC042550; AAH42550.1; -; mRNA.
DR   EMBL; BC044920; AAH44920.1; -; mRNA.
DR   CCDS; CCDS10735.1; -. [Q8IUQ4-1]
DR   CCDS; CCDS32444.1; -. [Q8IUQ4-2]
DR   RefSeq; NP_001006611.1; NM_001006610.1. [Q8IUQ4-2]
DR   RefSeq; NP_003022.3; NM_003031.3. [Q8IUQ4-1]
DR   RefSeq; XP_006721309.1; XM_006721246.1. [Q8IUQ4-1]
DR   RefSeq; XP_011521581.1; XM_011523279.1. [Q8IUQ4-1]
DR   UniGene; Hs.706828; -.
DR   PDB; 2A25; X-ray; 2.20 A; A=90-282.
DR   PDB; 4C9Z; X-ray; 1.95 A; A/B=91-282.
DR   PDB; 4CA1; X-ray; 1.58 A; A/B=91-282.
DR   PDB; 4I7B; X-ray; 3.00 A; A/C=90-282.
DR   PDB; 4I7C; X-ray; 2.80 A; A/C=90-282.
DR   PDB; 4I7D; X-ray; 2.40 A; A/C=90-282.
DR   PDB; 4X3G; X-ray; 2.34 A; A/B=91-282.
DR   PDBsum; 2A25; -.
DR   PDBsum; 4C9Z; -.
DR   PDBsum; 4CA1; -.
DR   PDBsum; 4I7B; -.
DR   PDBsum; 4I7C; -.
DR   PDBsum; 4I7D; -.
DR   PDBsum; 4X3G; -.
DR   ProteinModelPortal; Q8IUQ4; -.
DR   SMR; Q8IUQ4; -.
DR   BioGrid; 112372; 164.
DR   DIP; DIP-35684N; -.
DR   IntAct; Q8IUQ4; 125.
DR   MINT; MINT-156060; -.
DR   STRING; 9606.ENSP00000349156; -.
DR   iPTMnet; Q8IUQ4; -.
DR   PhosphoSitePlus; Q8IUQ4; -.
DR   BioMuta; SIAH1; -.
DR   DMDM; 46577493; -.
DR   EPD; Q8IUQ4; -.
DR   MaxQB; Q8IUQ4; -.
DR   PaxDb; Q8IUQ4; -.
DR   PeptideAtlas; Q8IUQ4; -.
DR   PRIDE; Q8IUQ4; -.
DR   DNASU; 6477; -.
DR   Ensembl; ENST00000356721; ENSP00000349156; ENSG00000196470. [Q8IUQ4-2]
DR   Ensembl; ENST00000380006; ENSP00000369343; ENSG00000196470. [Q8IUQ4-1]
DR   Ensembl; ENST00000394725; ENSP00000378214; ENSG00000196470. [Q8IUQ4-1]
DR   Ensembl; ENST00000568007; ENSP00000456421; ENSG00000196470. [Q8IUQ4-1]
DR   GeneID; 6477; -.
DR   KEGG; hsa:6477; -.
DR   UCSC; uc002efl.4; human. [Q8IUQ4-1]
DR   CTD; 6477; -.
DR   DisGeNET; 6477; -.
DR   GeneCards; SIAH1; -.
DR   HGNC; HGNC:10857; SIAH1.
DR   HPA; CAB018724; -.
DR   MIM; 602212; gene.
DR   neXtProt; NX_Q8IUQ4; -.
DR   OpenTargets; ENSG00000196470; -.
DR   PharmGKB; PA35759; -.
DR   eggNOG; KOG3002; Eukaryota.
DR   eggNOG; ENOG410XVP0; LUCA.
DR   GeneTree; ENSGT00390000005434; -.
DR   HOGENOM; HOG000231487; -.
DR   HOVERGEN; HBG055701; -.
DR   InParanoid; Q8IUQ4; -.
DR   KO; K04506; -.
DR   OMA; CRGSLGN; -.
DR   OrthoDB; EOG091G0BPY; -.
DR   PhylomeDB; Q8IUQ4; -.
DR   TreeFam; TF312976; -.
DR   BRENDA; 6.3.2.19; 2681.
DR   Reactome; R-HSA-373752; Netrin-1 signaling.
DR   Reactome; R-HSA-977225; Amyloid fiber formation.
DR   Reactome; R-HSA-983168; Antigen processing: Ubiquitination & Proteasome degradation.
DR   SIGNOR; Q8IUQ4; -.
DR   UniPathway; UPA00143; -.
DR   ChiTaRS; SIAH1; human.
DR   EvolutionaryTrace; Q8IUQ4; -.
DR   GeneWiki; SIAH1; -.
DR   GenomeRNAi; 6477; -.
DR   PRO; PR:Q8IUQ4; -.
DR   Proteomes; UP000005640; Chromosome 16.
DR   Bgee; ENSG00000196470; -.
DR   CleanEx; HS_SIAH1; -.
DR   ExpressionAtlas; Q8IUQ4; baseline and differential.
DR   Genevisible; Q8IUQ4; HS.
DR   GO; GO:0030877; C:beta-catenin destruction complex; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; TAS:ProtInc.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005769; C:early endosome; IEA:Ensembl.
DR   GO; GO:0005634; C:nucleus; ISS:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IEA:Ensembl.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0008022; F:protein C-terminus binding; IPI:UniProtKB.
DR   GO; GO:0061630; F:ubiquitin protein ligase activity; IDA:MGI.
DR   GO; GO:0004842; F:ubiquitin-protein transferase activity; IMP:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; IDA:UniProtKB.
DR   GO; GO:0009653; P:anatomical structure morphogenesis; TAS:ProtInc.
DR   GO; GO:0006915; P:apoptotic process; TAS:ProtInc.
DR   GO; GO:0007411; P:axon guidance; TAS:Reactome.
DR   GO; GO:0007049; P:cell cycle; IEA:UniProtKB-KW.
DR   GO; GO:0044267; P:cellular protein metabolic process; TAS:Reactome.
DR   GO; GO:0007399; P:nervous system development; TAS:ProtInc.
DR   GO; GO:0051402; P:neuron apoptotic process; ISS:UniProtKB.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:2001244; P:positive regulation of intrinsic apoptotic signaling pathway; IMP:UniProtKB.
DR   GO; GO:0043161; P:proteasome-mediated ubiquitin-dependent protein catabolic process; ISS:UniProtKB.
DR   GO; GO:0030163; P:protein catabolic process; IDA:UniProtKB.
DR   GO; GO:0031648; P:protein destabilization; IEA:Ensembl.
DR   GO; GO:0000209; P:protein polyubiquitination; TAS:Reactome.
DR   GO; GO:0042787; P:protein ubiquitination involved in ubiquitin-dependent protein catabolic process; ISS:UniProtKB.
DR   GO; GO:0007283; P:spermatogenesis; IEA:UniProtKB-KW.
DR   GO; GO:0006511; P:ubiquitin-dependent protein catabolic process; IDA:MGI.
DR   Gene3D; 2.60.210.10; -; 1.
DR   Gene3D; 3.30.40.10; -; 2.
DR   InterPro; IPR018121; 7-in-absentia-prot_TRAF-dom.
DR   InterPro; IPR004162; SINA-like.
DR   InterPro; IPR008974; TRAF-like.
DR   InterPro; IPR001841; Znf_RING.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   InterPro; IPR013010; Znf_SIAH.
DR   PANTHER; PTHR10315; PTHR10315; 1.
DR   Pfam; PF03145; Sina; 1.
DR   SUPFAM; SSF49599; SSF49599; 1.
DR   PROSITE; PS50089; ZF_RING_2; 1.
DR   PROSITE; PS51081; ZF_SIAH; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Apoptosis; Cell cycle;
KW   Complete proteome; Cytoplasm; Developmental protein; Differentiation;
KW   Metal-binding; Nucleus; Phosphoprotein; Reference proteome;
KW   Spermatogenesis; Transferase; Ubl conjugation pathway; Zinc;
KW   Zinc-finger.
FT   CHAIN         1    282       E3 ubiquitin-protein ligase SIAH1.
FT                                /FTId=PRO_0000056163.
FT   ZN_FING      41     76       RING-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00175}.
FT   ZN_FING      93    153       SIAH-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00455}.
FT   REGION       90    282       SBD.
FT   METAL        98     98       Zinc 1. {ECO:0000250}.
FT   METAL       105    105       Zinc 1. {ECO:0000250}.
FT   METAL       117    117       Zinc 1. {ECO:0000250}.
FT   METAL       121    121       Zinc 1. {ECO:0000250}.
FT   METAL       128    128       Zinc 2.
FT   METAL       135    135       Zinc 2.
FT   METAL       147    147       Zinc 2.
FT   METAL       152    152       Zinc 2.
FT   MOD_RES      19     19       Phosphoserine; by ATM and ATR.
FT                                {ECO:0000269|PubMed:18536714}.
FT   VAR_SEQ       1      1       M -> MTGKATPPSLYSWRGVLFTCLPAARTRKRKEM (in
FT                                isoform 2). {ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:17974005}.
FT                                /FTId=VSP_010166.
FT   VAR_SEQ     193    195       LEK -> DLS (in isoform 3).
FT                                {ECO:0000303|PubMed:17420721}.
FT                                /FTId=VSP_029210.
FT   VAR_SEQ     196    282       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:17420721}.
FT                                /FTId=VSP_029211.
FT   MUTAGEN      19     19       S->A: Impaired ATM mediated
FT                                phosphorylation, but normal interaction
FT                                with HIPK2 and HIPK2 subsequent
FT                                proteasomal degradation.
FT                                {ECO:0000269|PubMed:18536714}.
FT   MUTAGEN      19     19       S->D: Reduced interaction with HIPK2 and
FT                                HIPK2 subsequent proteasomal degradation.
FT                                {ECO:0000269|PubMed:18536714}.
FT   MUTAGEN      40     40       E->R: Loss of function.
FT                                {ECO:0000269|PubMed:9858595}.
FT   MUTAGEN      41     41       C->S: Loss of function; when associated
FT                                with S-44. {ECO:0000269|PubMed:9858595}.
FT   MUTAGEN      44     44       C->S: Loss of function.
FT                                {ECO:0000269|PubMed:18536714,
FT                                ECO:0000269|PubMed:9858595}.
FT   MUTAGEN      55     55       C->A: Loss of function; when associated
FT                                with A-59 and S-72.
FT                                {ECO:0000269|PubMed:15064394,
FT                                ECO:0000269|PubMed:9858595}.
FT   MUTAGEN      55     55       C->S: Loss of function; when associated
FT                                with Y-59. {ECO:0000269|PubMed:15064394,
FT                                ECO:0000269|PubMed:9858595}.
FT   MUTAGEN      59     59       H->A: Loss of function; when associated
FT                                with A-55 and S-72.
FT                                {ECO:0000269|PubMed:15064394,
FT                                ECO:0000269|PubMed:9858595}.
FT   MUTAGEN      59     59       H->Y: Loss of function.
FT                                {ECO:0000269|PubMed:15064394,
FT                                ECO:0000269|PubMed:9858595}.
FT   MUTAGEN      66     66       R->L: Decreased activity; when associated
FT                                with T-68. {ECO:0000269|PubMed:9858595}.
FT   MUTAGEN      68     68       K->T: Decreased activity; when associated
FT                                with L-66. {ECO:0000269|PubMed:9858595}.
FT   MUTAGEN      72     72       C->S: Loss of function; when associated
FT                                with A-55 and A-59.
FT                                {ECO:0000269|PubMed:15064394}.
FT   MUTAGEN      76     76       R->E: Decreased activity.
FT                                {ECO:0000269|PubMed:9858595}.
FT   MUTAGEN     124    124       R->A: In D; does not impair its ability
FT                                to interact with CACYBP and degrade
FT                                CTNNB1 and PML; when associated with A-
FT                                214; A-215; A-231 and A-232.
FT   MUTAGEN     142    142       D->A: In E; does not impair its ability
FT                                to interact with CACYBP and degrade
FT                                CTNNB1; when associated with A-151.
FT   MUTAGEN     151    151       Q->A: In E; does not impair its ability
FT                                to interact with CACYBP and degrade
FT                                CTNNB1; when associated with A-142.
FT   MUTAGEN     152    152       H->Y: Abolishes ability to degrade DCC.
FT                                {ECO:0000269|PubMed:9858595}.
FT   MUTAGEN     161    162       ED->AA: In A; does not impair its ability
FT                                to degrade PML while it abolishes its
FT                                ability to interact with CACYBP and
FT                                degrade CTNNB1; when associated with A-
FT                                226 and A-237.
FT   MUTAGEN     198    200       KYD->GDG: Impairs CTNNB1 degradation.
FT                                {ECO:0000269|PubMed:16085652}.
FT   MUTAGEN     202    202       H->Y: No effect.
FT                                {ECO:0000269|PubMed:9858595}.
FT   MUTAGEN     211    211       L->R: Abolishes ability to degrade DCC.
FT                                {ECO:0000269|PubMed:9858595}.
FT   MUTAGEN     214    215       TR->AA: In D; does not impair its ability
FT                                to interact with CACYBP and degrade
FT                                CTNNB1 and PML; when associated with A-
FT                                124; A-231 and A-232.
FT   MUTAGEN     224    224       R->A: In C; does not impair its ability
FT                                to interact with CACYBP and degrade
FT                                CTNNB1; when associated with A-233.
FT   MUTAGEN     226    226       E->A: In A; does not impair its ability
FT                                to degrade PML while it abolishes its
FT                                ability to interact with CACYBP and
FT                                degrade CTNNB1; when associated with A-
FT                                161; A-162 and A-237.
FT   MUTAGEN     231    232       RR->AA: In D; does not impair its ability
FT                                to interact with CACYBP and degrade
FT                                CTNNB1 and PML; when associated with A-
FT                                124; A-214 and A-215.
FT   MUTAGEN     233    233       R->A: In C; does not impair its ability
FT                                to interact with CACYBP and degrade
FT                                CTNNB1; when associated with A-233.
FT   MUTAGEN     237    237       E->A: In A; does not impair its ability
FT                                to degrade PML while it abolishes its
FT                                ability to interact with CACYBP and
FT                                degrade CTNNB1; when associated with A-
FT                                161; A-162 and A-226.
FT   MUTAGEN     252    252       M->D,K: Impairs CTNNB1 degradation.
FT                                {ECO:0000269|PubMed:16085652}.
FT   MUTAGEN     253    253       N->A: In B; does not impair its ability
FT                                to interact with CACYBP and degrade
FT                                CTNNB1; when associated with A-265.
FT   MUTAGEN     265    265       Q->A: In B; does not impair its ability
FT                                to interact with CACYBP and degrade
FT                                CTNNB1; when associated with A-253.
FT   CONFLICT    173    173       P -> S (in Ref. 5; CAE46191).
FT                                {ECO:0000305}.
FT   CONFLICT    245    245       E -> G (in Ref. 5; CAE46191).
FT                                {ECO:0000305}.
FT   STRAND       95     97       {ECO:0000244|PDB:4X3G}.
FT   HELIX       101    103       {ECO:0000244|PDB:4CA1}.
FT   STRAND      108    110       {ECO:0000244|PDB:4X3G}.
FT   HELIX       111    120       {ECO:0000244|PDB:4CA1}.
FT   STRAND      122    124       {ECO:0000244|PDB:4I7B}.
FT   STRAND      130    134       {ECO:0000244|PDB:4CA1}.
FT   HELIX       141    143       {ECO:0000244|PDB:4CA1}.
FT   HELIX       144    151       {ECO:0000244|PDB:4CA1}.
FT   STRAND      156    167       {ECO:0000244|PDB:4CA1}.
FT   STRAND      172    184       {ECO:0000244|PDB:4CA1}.
FT   STRAND      187    197       {ECO:0000244|PDB:4CA1}.
FT   STRAND      203    213       {ECO:0000244|PDB:4CA1}.
FT   HELIX       215    218       {ECO:0000244|PDB:4CA1}.
FT   STRAND      221    229       {ECO:0000244|PDB:4CA1}.
FT   STRAND      232    238       {ECO:0000244|PDB:4CA1}.
FT   TURN        243    245       {ECO:0000244|PDB:4CA1}.
FT   HELIX       248    252       {ECO:0000244|PDB:4CA1}.
FT   STRAND      256    260       {ECO:0000244|PDB:4CA1}.
FT   HELIX       261    267       {ECO:0000244|PDB:4CA1}.
FT   STRAND      272    281       {ECO:0000244|PDB:4CA1}.
SQ   SEQUENCE   282 AA;  31123 MW;  FA0698D0DC1B0A15 CRC64;
     MSRQTATALP TGTSKCPPSQ RVPALTGTTA SNNDLASLFE CPVCFDYVLP PILQCQSGHL
     VCSNCRPKLT CCPTCRGPLG SIRNLAMEKV ANSVLFPCKY ASSGCEITLP HTEKADHEEL
     CEFRPYSCPC PGASCKWQGS LDAVMPHLMH QHKSITTLQG EDIVFLATDI NLPGAVDWVM
     MQSCFGFHFM LVLEKQEKYD GHQQFFAIVQ LIGTRKQAEN FAYRLELNGH RRRLTWEATP
     RSIHEGIATA IMNSDCLVFD TSIAQLFAEN GNLGINVTIS MC
//
